Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact

Content Update

December 21, 2023

Reacting to the Rise of Respiratory Syncytial Virus: An Update on Prevention: In 2023, the U.S. Food and Drug Administration (FDA) approved several prophylactic measures against the respiratory syncytial virus (RSV): 1) Nirsevimab (Beyfortus®) for the pediatric population; 2) a recombinant, adjuvanted RSVPreF3 vaccine (Arexvy®) for the geriatric population; and 3) a bivalent RSVpreF vaccine (Abrysvo®) for the pregnant and geriatric populations. Compared to palivizumab, the previous standard of care, nirsevimab has an extended half-life and convenient single-dosing schedule. Abrysvo® and Arexvy® are recommended by the Centers for Disease Control and Prevention (CDC) as single dose RSV vaccine options for adults 60 and older with shared decision making. Additionally, Abrysvo® is recommended in pregnant women at 32-36 weeks gestational age. Adverse effects (AEs) were mostly minor, although neurological AEs (e.g. Guillain-Barre syndrome) were noted in a small number of patients.

Content Update

March 15, 2023

Inpatient Management of COVID-19: The National Institutes of Health (NIH) frequently release COVID-19 guideline updates to assist with the diagnosis, treatment and management of patients infected with COIVD-19. The management of inpatients with COVID-19 varies greatly depending on patient risk factors, disease severity and medication availability. Pharmacologic treatment involves a variety of therapies that target different pathologic mechanisms including antivirals, anti-inflammatory agents, and immunomodulatory agents, This update will focus on new pharmacotherapy recommendations regarding the inpatient management of COVID-19.

Content Update

September 29, 2022

Approval of the Combination Nirmatrelvir/Ritonavir (Paxlovid™) for the Treatment of COVID-19 in the Outpatient Setting: In December 2021, the treatment combination nirmatrelvir/ritonavir (Paxlovid™) received emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in adults and children over 12 years of age. The combination pill consists of nirmatrelvir, a 3C-like protease inhibitor which inhibits viral replication, and ritonavir, a protease inhibitor with pharmacokinetic boosting effects. Certain patient criteria must be met prior to prescribing. As of July 6, 2022, the EUA was revised giving licensed pharmacists prescriptive authority for the agent.



Upon completion of the chapter, the reader will be able to:

  1. List the common pathogens that cause community-acquired pneumonia (CAP), ventilator-associated pneumonia (VAP), and hospital-acquired pneumonia (HAP).

  2. Explain the pathophysiology of pneumonia and associated host defenses.

  3. List the signs and symptoms associated with CAP, HAP, and VAP.

  4. Identify patient and organism factors required to guide the selection of a specific antimicrobial regimen for an individual patient.

  5. Design an appropriate empirical antimicrobial regimen based on patient-specific data for an individual with CAP, HAP, and VAP.

  6. Design an appropriate antimicrobial regimen based on both patient- and organism-specific data.

  7. Develop a monitoring plan based on patient-specific information for a patient with one of the three categories of pneumonia.

  8. Apply the complete Patient Care Process to caring for patients with ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.